Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.

A 19-year-old concerned about long-term effects of 5AR inhibitors on physical appearance. They have used finasteride and plan to try dutasteride or RU58841; responses suggest improved skin, hair, and confidence.

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

Switching finasteride brands from Teva to Proscar led to hair and skin issues, suggesting possible differences in effectiveness or quality. Users recommend returning to the original brand that worked well.

The conversation discusses concerns that Minoxidil may cause skin aging, like collagen depletion and puffier faces. Some users suggest that a good skincare routine or collagen supplements might prevent these effects.

Hair loss after telogen effluvium (TE) with thinning and possible scarring, treated with 5 mg oral minoxidil. Concerns about scarring alopecia and lack of regrowth, with suggestions to consider finasteride for better results.

After nearly four months on finasteride, a user noticed improved hair quality but developed nipple puffiness, suggesting early signs of gynecomastia. They considered switching to other treatments like CB-03-01 or RU58841 and contemplated consulting an endocrinologist about aromatase inhibitors.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

The conversation is about using Bimatoprost for hair growth, with concerns about potential side effects like eye color change and fat atrophy. Users discuss combining it with other treatments like Minoxidil and Finasteride, and sourcing Bimatoprost in bulk.

Scalp micropigmentation (SMP) is a viable option for those experiencing hair loss, providing a natural look similar to a buzzcut. It requires touch-ups every 3-5 years, and using products like zero shine can help manage appearance issues in different lighting.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. UC Irvine scientists discover possible baldness cure.

Stem cell and exosome injections for hair loss are discussed, with skepticism about their effectiveness and concerns about using non-genetically related stem cells. Dr. Deyarmin's treatments are mentioned, with some users questioning their legitimacy and others expressing curiosity.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

A user experienced significant swelling after a hair and beard transplant, possibly due to an allergic reaction or improper post-surgery care. Despite dissatisfaction with the clinic's handling of grafts and customer service, the user appreciates the clinic's skill in achieving natural hairline density.

Cecred hair drops, containing keratin and biotin, are questioned for their effectiveness compared to proven treatments like minoxidil. Users express skepticism, suggesting deceptive marketing and the possibility of undisclosed use of other treatments like finasteride.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

User shared progress in treating hair loss and improving skin, using treatments like finasteride, minoxidil, RU58841, tretinoin, microneedling, and skin care regimen. Others commented on the impressive results and asked about costs and side effects.

The conversation critiques the influence of "Clavicular" on young men regarding hair loss treatments, highlighting the dangers of following unscientific advice and the rise of body dysmorphia. It emphasizes the importance of safe, medically advised treatments like minoxidil, finasteride, and dutasteride, while warning against reckless experimentation and early surgeries.

Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.

The conversation is about the potential aging effects of oral minoxidil on the skin. Users discuss their experiences, with some attributing skin changes to aging rather than minoxidil, and mention using tretinoin to improve skin appearance.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

User started minoxidil, noticed forehead lines and dark circles, and asked for non-invasive skin aging prevention methods. Another user suggested using tretinoin and hyaluronic acid for long-term benefits.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

Scalp tattoos can look good but often appear artificial, especially in sunlight or up close, and require regular maintenance. They may boost confidence if done well, but opinions vary on their effectiveness and natural appearance.